The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Abstract
Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer. Objective: The objective of the study was to investigate the prognostic value of BRAF mutation in patients with PTC. Design, Setting, and Subjects: In a multicenter study of 219 PTC patients, data on their clinicopathological characteristics and clinical courses between 1990 and 2004 were retrospectively collected, and their tumor BRAF mutation status was determined. Associations of BRAF mutation with initial tumor characteristics and subsequent recurrence were analyzed. Main Outcome Measure: Relationships between the BRAF mutation status and clinicopathological outcomes, including recurrence, were measured. Results: We found a significant association between BRAF mutation and extrathyroidal invasion (P < 0.001), lymph node metastasis (P < 0.001), and advanced tumor stage III/IV (P = 0.007) at initial surgery. This association remained significant on multivariate analysis, adjusting for conventional clinicopathological predictors of recurrence excluding the histological PTC subtype, but was lost when the tumor subtype was included in the model. BRAF mutation was also significantly associated with tumor recurrence, 25 vs. 9% with and without mutation, respectively (P = 0.004), during a median of 15 (interquartile range, 3–29) months of follow-up. This association remained significant on multivariate analysis adjusting for conventional clinicopathological predictors of recurrence, even including the PTC subtype (odds ratio, 4.0; 95% confidence interval, 1.1–14.1; P = 0.03). BRAF mutation was even an independent predictor of recurrence in patients with stage I/II disease, 22 vs. 5% with and without BRAF mutation, respectively (P = 0.002). BRAF mutation was also more frequently associated with absence of tumor I-131 avidity and treatment failure of recurrent disease. Conclusions: In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence. Therefore, BRAF mutation may be a useful molecular marker to assist in risk stratification for patients with PTC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationHAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Self-citationGilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
National Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
Self-citationGiordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., & Sobrinho‐Simões, M. (2004) · The Journal of Pathology · doi:10.1002/path.1511 · Cited by 363
Hay, I. D., Grant, C. S., Bergstralh, E. J., Thompson, G. B., van Heerden, J. A., & Goellner, J. R. (1998) · Surgery · doi:10.1016/s0039-6060(98)70035-2 · Cited by 329
BRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
Hilger, R. A., Scheulen, M. E., & Strumberg, D. (2002) · Oncology Research and Treatment · doi:10.1159/000068621 · Cited by 265
BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Salvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
Trovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
Xing, M., Tufano, R. P., Tufaro, A. P., Basaria, S., Ewertz, M., Rosenbaum, E., Byrne, P. J., Wang, J., Sidransky, D., & Ladenson, P. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032050 · Cited by 251
Self-citationMutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
Kim, K. H., Kang, D. W., Kim, S. H., Seong, I. O., & Kang, D. Y. (2004) · Yonsei Medical Journal · doi:10.3349/ymj.2004.45.5.818 · Cited by 229
Fahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Cohen, Y., Rosenbaum, E., Clark, D. P., Zeiger, M. A., Umbricht, C. B., Tufano, R. P., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0273 · Cited by 207
Self-citationBRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D., & Westra, W. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800198 · Cited by 175
Self-citationXing, M., Usadel, H., Cohen, Y., Tokumaru, Y., Guo, Z., Westra, W. B., Tong, B. C., Tallini, G., Udelsman, R., Califano, J. A., et al. (2003) · PubMed · Cited by 151
Self-citationXing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P. W., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3242 · Cited by 143
Self-citationBRAF T1796A Transversion Mutation in Various Thyroid Neoplasms
Xing, M., Vasko, V. V., Tallini, G., Ларін, О. С., Wu, G., Udelsman, R., Ringel, M. D., Ladenson, P. W., & Sidransky, D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031488 · Cited by 127
Self-citationPorra, V., Ferraro‐Peyret, C., Durand, C., Selmi‐Ruby, S., Giroud, H., Berger-Dutrieux, N., Decaussin‐Petrucci, M., Peix, J., Bournaud, C., Orgiazzi, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1394 · Cited by 108
Kondo, N. I., Shimada, M., & Fukatsu, T. (1999) · ZOOLOGICAL SCIENCE · doi:10.2108/zsj.16.955 · Cited by 97
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Self-citationMolecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Metadata
- Authors
- Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E. H., Hui, P., Umbricht, C. B., Basaria, S., Ewertz, M., Tufaro, A. P., Califano, J. A., Ringel, M. D., Zeiger, M. A., Sidransky, D., & Ladenson, P. W.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-12-01
- Volume
- 90
- Issue
- 12
- Pages
- 6373-6379
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2171379946
- Cited by
- 993
- References
- 37
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.